CA-PICSART
6.4.2021 14:02:11 CEST | Business Wire | Press release
PicsArt , the world’s largest creative platform, today announced the opening of its newest office in the U.K. Headquartered in San Francisco, PicsArt’s workforce spans the globe with growing offices and employees in Yerevan, Armenia, Los Angeles, Moscow, Beijing, Tokyo and India. In the past year alone, PicsArt has expanded its employee headcount by 36%. Establishing a new office in the U.K. is PicsArt’s latest move in its strategy to meet the needs of its user base of more than 150 million monthly active creators worldwide.
The announcement follows PicsArt’s recent hiring of its VP of Design, acclaimed designer Duncan Riley, who is based in the U.K. In this role, Riley will lead the expansion of the new hub, which will be focused on Product Development and Design. Riley brings more than 18 years of experience growing creative teams and crafting global user experiences for a host of leading brands, including Shazam, Skyscanner, Snapchat, NBCUniversal, Viacom, Absolute Radio and more.
“At PicsArt we are building the best all-round creator experience possible, allowing anyone and everyone to perfect their everyday moments, express their passions, promote their business, or even create art. I'm excited to get started with the incredible talent here at PicsArt, and begin growing the UK-based team to support our vision in 2021,” Riley shared.
Of the buildout, PicsArt founder and CEO Hovhannes Avoyan says, “As a globally-minded and operated company of more than 700 employees, our goal is to best serve the many ways PicsArt creators use our product across the world. We are excited to come to the U.K. and welcome new members and all of their insights and contributions to build amazing things together for our active and dynamic user base.”
In addition to hiring for its new U.K. hub, PicsArt is actively hiring in other global regions - including remote-based positions - in design, engineering, product operations, marketing, content, and more. For more information on current open roles, prospective applicants can visit https://picsart.com/jobs .
About PicsArt
PicsArt is the world’s #1 creative platform and a top 20 most downloaded app for seven consecutive quarters. Every month, the PicsArt community creates, remixes and shares billions of visual stories using the company’s powerful and easy-to-use editing tools. PicsArt has amassed one of the largest open-source content collections in the world, including free-to-edit photos, stickers, backgrounds, templates and more. PicsArt is available in 30 languages for free and as a subscription on iOS, Android and Windows devices. PicsArt is backed by Sequoia Capital, DCM Ventures, Insight Partners, and Siguler Guff & Company. Download the app or visit picsart.com or picsart.com/brands/ for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005093/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom